Man-Dox

Man-Dox is an investigational **CD206-targeted doxorubicin conjugate** in Navidea's Manocept therapeutic platform, designed to deliver doxorubicin to **CD206-positive macrophages**, particularly tumor-associated macrophages in the tumor microenvironment. The construct uses a **mannosylated dextran backbone** to bind the macrophage mannose receptor and is intended to deplete or reprogram immunosuppressive macrophages toward a more pro-inflammatory, tumoricidal phenotype while also providing localized cytotoxic anthracycline exposure. Publicly available information indicates preclinical oncology development by Navidea, with reported activity in vitro and in animal models, including synergy with checkpoint immunotherapy.

Other names

Manocept doxorubicinCD206-targeted doxorubicin constructCD-206-targeted doxorubicin constructCD 206-targeted doxorubicin constructdoxorubicin linked to a mannosylated dextran backbone